Capstone Therapeutics Corp Common Stock (CAPS) Announces Earnings Results

Capstone Therapeutics Corp Common Stock (OTCMKTS:CAPS) issued its quarterly earnings results on Monday. The biotechnology company reported $0.02 earnings per share for the quarter, Bloomberg Earnings reports. The company had revenue of $2.00 million during the quarter.

Shares of OTCMKTS:CAPS remained flat at $$0.05 during midday trading on Wednesday. 4,010 shares of the stock were exchanged, compared to its average volume of 3,413. Capstone Therapeutics Corp Common Stock has a one year low of $0.04 and a one year high of $0.09. The company has a quick ratio of 4.40, a current ratio of 4.40 and a debt-to-equity ratio of -1.57.

About Capstone Therapeutics Corp Common Stock



Capstone Therapeutics Corp., a biotechnology company, develops and sells novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism.

Read More: How to Invest in Marijuana Stocks

Earnings History for Capstone Therapeutics Corp Common Stock (OTCMKTS:CAPS)

Receive News & Ratings for Capstone Therapeutics Corp Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capstone Therapeutics Corp Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply